TrialClinical and translational science2022

A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.

Yuji Orito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.